Citius Oncology (CTOR) Assets Average (2023 - 2026)
Citius Oncology (CTOR) posted quarterly Assets Average of $105.3 million for Q1 2026, up 15.8% year-over-year from $91.0 million in Q1 2025, and little changed quarter-over-quarter from $105.5 million in Q4 2025.
Citius Oncology (CTOR) Assets Average (2023 - 2026) Analysis & Trends
Citius Oncology (CTOR) has reported Assets Average for 4 consecutive years, with $105.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 15.8% year-over-year to $105.3 million; the TTM figure through Mar 2026 stood at $105.3 million (up 15.8% YoY), while the FY2025 annual figure was $92.7 million, up 18.04% from the prior year.
- Assets Average was little changed at $105.3 million in Q1 2026 per CTOR's latest filing, from $105.5 million in the prior quarter.
- Across five years, Assets Average topped out at $105.5 million in Q4 2025 and bottomed at $48.9 million in Q2 2024.
- Historically, Assets Average has averaged $77.7 million across 4 years, with a median of $69.3 million in 2023.
- Annual changes were most pronounced in 2024 — Assets Average decreased 29.42% — and 2025, when it jumped 87.13%.
- Citius Oncology's Assets Average stood at $60.2 million in 2023, then soared by 45.27% to $87.4 million in 2024, then rose by 20.63% to $105.5 million in 2025, then decreased by 0.12% to $105.3 million in 2026.
- Business Quant data shows CTOR's Assets Average at $105.3 million in Q1 2026, $105.5 million in Q4 2025, and $96.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | 43.72 Bn |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | 39.95 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 15.12 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 98.59 Bn |
| 5 | United Therapeutics | 22.19 Bn | 19.53 Bn | 683.80 Mn | 6.97 Bn |
| 6 | Viatris | 18.68 Bn | 17.79 Bn | 1.46 Bn | 35.94 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 5.13 Bn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 13.39 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 5.97 Bn |
| 10 | Citius Oncology | 79.84 Mn | 79.84 Mn | 1.00 Mn | 106.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 105.34 Mn |
| Dec 31, 2025 | 105.46 Mn |
| Sep 30, 2025 | 96.33 Mn |
| Jun 30, 2025 | 91.57 Mn |
| Mar 31, 2025 | 90.96 Mn |
| Dec 31, 2024 | 87.43 Mn |
| Sep 30, 2024 | 66.78 Mn |
| Jun 30, 2024 | 48.94 Mn |
| Mar 31, 2024 | 60.65 Mn |
| Dec 31, 2023 | 60.18 Mn |
| Sep 30, 2023 | 58.79 Mn |
| Jun 30, 2023 | 69.33 Mn |
| Mar 31, 2023 | 68.50 Mn |